快验保 MED 深 沪
已收盘 05-22 16:00:00 美东时间
12.59
-0.040
-0.32%
华盛通- 最 高13.00
- 今 开12.65
- 成交量 12.79万股
- 最 低 12.52
- 昨 收 12.63
- 总市值 1.40亿
- 52周最高 15.46
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 9.22
- 委 比 33.33%
- 总股本 1111.91万
- 历史最高 321.22
- 量 比 0.79
- 振 幅 3.80%
- 历史最低 -17.07
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
OPTAVIA's weight loss program emphasizes body composition, targeting visceral fat reduction and lean mass preservation for long-term metabolic health. Structured meal plans, high-quality protein, and coach support are key to achieving sustainable weight loss. Research shows participants in OPTAVIA's program lost 14% visceral fat and retained 98% lean mass in 16 weeks, outperforming independent weight loss attempts.
05-15 17:00
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
The global weight loss industry was valued at $16.3 billion in 2025, but peer-reviewed clinical validation of program outcomes remains inconsistent. OPTA VIA, a science-backed, coach-guided metabolic health system, emphasizes the importance of randomized controlled trials and body composition analysis to ensure clinically proven results. Their studies show that clients on the Optimal Weight 5 & 1 Plan® retained 98% of lean mass and lost 10 times ...
05-15 17:00
Medifast shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 EPS and FY2026 sales guidance.
Medifast shares are trading higher after the company reported better-than-expec...
05-05 23:24
Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est
Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.98) analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$300.000 million to $270.000 million-$300.000
05-05 04:08
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
Gainers Medifast (NYSE:MED) stock increased by 9.9% to $12.0 during Wednesday'...
04-30 05:06
Medifast Agrees To Nominate Steamboat Capital Partners' Parsa Kiai, Jeff Rose As Independent Director Candidates
Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and
03-20 20:34
Medifast adds Steamboat nominees to board slate to boost stockholder value at May 19, 2026 meeting
Medifast adds Steamboat nominees to board slate to boost stockholder value at May 19, 2026 meeting Medifast reached a cooperation agreement with Steamboat Capital, which said it beneficially owns above 5% of the company’s outstanding shares. Board nominations under the agreement include Parsa Kiai a
03-20 20:30
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.
03-17 19:12
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
